Japan Approves First Stem-Cell Therapy for Parkinson’s Disease
Japan has approved a groundbreaking stem-cell therapy for Parkinson’s disease, marking a major milestone in regenerative medicine. The Japanese government also cleared a similar treatment for severe heart failure, potentially making them the world’s first commercially available medical products based on induced pluripotent stem (iPS) cells. The therapies are expected to reach patients within months, reflecting Japan’s growing leadership in advanced biomedical innovation. Parkinson’s Therapy Using Stem Cells Japanese pharmaceutical company Sumitomo Pharma received approval to manufacture and market a Parkinson’s treatment called Amchepry. The therapy involves transplanting laboratory-grown stem cells directly into a patient’s brain. These stem cells are developed into precursors of dopamine-producing neurons. In Parkinson’s disease , these neurons gradually deteriorate, leading to symptoms such as tremors, stiffness, and difficulty in movement. By replacing these damaged cells, th...